PLoS ONE · 2017 · 32 citations · 20 references
MedicineMolecular BiologyOncologyMolecular DiagnosticsMolecular OncologyTumor ProgressionCancer BiomarkersCancer GenomicsCancer Molecular DiagnosticsCirculating Tumor Dna AnalysisMolecular Tumor ProfilingNext-generation Sequencing In OncologyAllelic Fraction QuantificationCirculating Cell-free Dna AnalysisCirculating Tumor Dna DetectionCirculating Tumor Dna TestingEgfr Mutation TestingResistance Mutation DetectionTherapeutic Tyrosine Kinase InhibitorsTumor Mutation Detection
Over the past years, targeted therapies using tyrosine kinase inhibitors (TKI) have led to an increase in progression-free survival and response rate for a subgroup of non-small cell lung cancer (NSCLC) patients harbouring specific gene abnormalities compared with chemotherapy. However long-lasting tumor regression is rarely achieved, due to the development of resistant tumoral subclones, which requires alternative therapeutic approaches. Molecular profile at progressive disease is a challenge for making adaptive treatment decisions. The aim of this study was to monitor EGFR-mutant tumors over time based on the quantity of mutant DNA circulating in plasma (ctDNA), comparing two different methods, Crystal™ Digital™ PCR and Massive Parallel Sequencing (MPS). In plasma circulating cell free DNA (cfDNA) of 61 advanced NSCLC patients we found an overall correlation of 78% between mutated allelic fraction measured by Crystal Digital PCR and MPS. 7 additional samples with sensitizing mutations and 4 additional samples with the resistance mutation were detected with Crystal Digital PCR, but not with MPS. Monitoring levels of both mutation types over time showed a correlation between levels and trends of mutated ctDNA detected and clinical assessment of disease for the 6 patients tested. In conclusion, Crystal Digital PCR exhibited good performance for monitoring mutational status in plasma cfDNA, and also appeared as better suited to the detection of known mutations than MPS in terms of features such as time to results.
20
Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +12
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text
Medicine, Oncology, Pharmacology +16
Circulating mutant DNA to assess tumor dynamics
Frank Diehl, Kerstin Schmidt, Michael A. Choti et al. · Nature Medicine · 2008 · 2.7K citations · Full text